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1. Introduction 
The number of patients with bone defects due to diseases, tumors, and trauma has increased 
gradually in recent years. According to the American Academy of Orthopedic Surgeons, 
approximately 2.2 million of musculoskeletal procedures involving bone grafting are done 
annually worldwide
1
. Although autologous bone transplantation is the gold standard, donor site 
morbidity and the limitation of available volume lead to an important need for developing 
fully-functional artificial bones. Scaffolds with MSC-derived osteogenic cells are currently 
commercially available (trinity evolution, osteocell, Map3, BIO4/Stryker, etc.); however, there 
is insufficient evidence for the real therapeutic effect of these engineered grafts.  
Pluripotent stem cells are defined by two characteristics: self-renewal and pluripotency. 
Embryonic stem cells (ESCs), which exist only at the earliest stages of development, and 
induced pluripotent stem cells (iPSCs), which have been reprogramed from somatic cells, can 
give rise to any cell type of the embryonic proper. Upon osteogenic differentiation, human 
iPSC-derived osteoblasts (hiPSCs-OB) have shown higher proliferation rate as well as improved 
osteogenic features in vitro than those derived from MSCs
2, 3
. Therefore, there is a growing 
interest for developing effective systems to achieve osteoblast specification of PSCs
4,5,6
. 
However, none of strategies developed so far is a fully xeno-free, which is crucial for safe 
clinical translation. Based on this need, the present study aims to establish an effective protocol 
for osteoblast differentiation from hiPSCs by using small molecule inducers under fully defined, 
xeno-free, and 3D conditions. 
 
2. Experimental  
2.1. Reagents 
The following small molecules were used for manipulation of specific signaling pathways. 
PD0325901 for inhibiting mitogen-activated protein kinase kinase, CHIR99021 (CHIR) for 
activating canonical Wnt signaling. Smoothened agonist (SAG) and cyclopamine (Cyc) for 
activating and repressing hedgehog (Hh) signaling, respectively. BMP-dependent osteogenic 
molecule TH was also used
7
.  
2.2 Mouse pluripotent stem cell (mPSCs) culture 
Mouse PSCs including mESCs and miPSCs were maintained on gelatin-coated culture dishes 
(2D PSCs) under the 2iLIF culture conditions described previously
8
. An atelocollagen porous 
scaffold (Mighty sponge, KOKEN CO., LTD) was used for 3D PSC cultures under the same 
culture conditions. Subsequent osteoblast differentiation was carried out as previously reported
4
.  
2.3. Human induced pluripotent stem cell (iPSC) culture  
Three independently derived human iPSC lines maintained in Essential 8™ medium (Thermo 
Fisher Scientific) on vitronectin-coated dishes were used for developing the osteoblast induction 
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method using small molecule inducers. For 3D cultures, porous scaffolds fabricated from human 
collagen I-based recombinant peptide (Cellnest™, Fujifilm) were used. 
 
3. Results and discussion  
3.1. Establishment of a three-dimensional (3D) culture system for osteogenic 
differentiation of pluripotent stem cells 
To elucidate the relevant features of the 3D culture of PSCs, I cultured mESCs and miPSCs with 
atelocollagen scaffolds and compared them with those cultured in conventional gelatin-coated 
plates in terms of pluripotency maintenance and differentiation under defined conditions.   
3D mESCs strongly expressed pluripotency markers (Nanog, Oct4, Sox2) at 
comparable levels to 2D mESCs. However, 3D mESCs maintained expressions of all 
pluripotency markers tested in the absence of 2iLIF, whereas 2D mESCs showed 
downregulation of those genes. Thus, 3D culture can maintain mESCs in an undifferentiated 
state with the self-renewal capacity even in the absence of exogenous stimulation. 
Next, I evaluated the differentiation potential of 3D mESCs. Gene expression patterns 
in the osteogenic 3D culture, in comparison with those in the osteogenic 2D culture, showed 
similar trend. Pluripotency markers were progressively downregulated while the osteogenic 
markers were gradually upregulated throughout the osteoblast induction. In contrast, Dmp1 and 
Sost (osteocyte markers) were highly expressed in the osteogenic 3D culture on days 19 and 26, 
but not in the 2D culture, compared to day 0 (Figure 1A). Immunohistochemistry of the 
cell-scaffold complex showed nuclear localization of SP7 in most of the cells, and superficial 
cell clusters expressing DMP-1 (Figure 1B). The von Kossa staining with nuclear fast red 
staining revealed cells embedded in the calcified ECM within the scaffold, and SEM 
examination highlighted calcium nodule-like structures covering the ECM (Figure 1C). 
Thus, mESCs successfully underwent small molecule-mediated, terminal differentiation into 
mature osteoblasts and osteocytes in the 3-D culture. Unlike the 2-D culture, the osteogenic 3-D 
culture further induced maturation of osteoblasts into osteocytes. Also, the present 3-D culture 
platform successfully worked in miPSCs. 
Figure 1. (A) mRNA expression determined by RT-qPCR analysis in the osteocyte 
markers 2-D (white bars) or 3-D (black bars) cultures of mESCs. The data are 
expressed as the mean ± SDs from six independent experiments. *p < 0.001. (B) 
SP7 and DMP1 protein expression in the osteogenic 3-D culture of mESCs. Nuclei 
were stained with DAPI. Scale bars, 100 μm. (C) Representative picture of von 
Kossa staining with nuclear fast red (upper panel), and SEM (lower panel). Scale 
bars, 50 μm and 5 μm, respectively. 
 
3.2. Development of a fully-defined, xeno-free protocol for osteogenic differentiation of 
human induced pluripotent stem cells (iPSCs)  
Although the strategy used above leads the differentiation and maturation of mouse PSCs into 
osteoblasts even in 3-D cultures, it fails to produce terminal osteoblast commitment and 
maturation in hiPSCs. Since sustained activation of the Hh signaling has been shown to inhibit 
osteoblast commitment in human mesenchymal stem cells
10
, treatment with SAG was restricted 
just for the specification to osteoblast precursors upon mesoderm induction (phase I). In contrast, 
the removal of canonical Wnt signaling in early osteoblast progenitors was reported to inhibit 
the terminal osteoblast differentiation
11
. Therefore, a subsequent treatment with CHIR was 
considered for the optimization of the present strategy (phase II), followed by 9 extra days of 
culture without any inducer (phase III). Figure 2A shows the improved strategy.  
 
Figure 2. (A) A schematic showing the developed 
strategy for inducing osteogenic differentiation of 
hiPSCs. (B) mRNA expression determined by 
RT-qPCR analysis of the osteogenic markers. The data 
are expressed as the mean ± SDs from four 
independent experiments.  
 
 
The hiPSCs maintained under a feeder-free condition were subjected to the developed protocol. 
The contribution of the Wnt/β-catenin signaling activation by using CHIR to the middle stage of 
osteoblast differentiation (from day 10 to day 12) was verified by mRNA expression analysis; 
stage specific treatment with SAG and CHIR (SAG, CHIR) exerted stronger effects on 
osteoblast differentiation than sustained SAG treatment (SAG) as indicated by the upregulation 
of osteoblast markers at day 21 (Figure 3B). In addition, this improved chemically defined 
xeno-free strategy allowed the successful differentiation of three independent hiPSC lines into 
functional osteoblasts. 
 
3.2. Development of a fully-defined, xeno-free protocol for osteogenic differentiation of 
human induced pluripotent stem cells (iPSCs)  
To investigate whether the optimized xeno-free strategy can be applied to differentiate hiPSCs 
into osteoblasts under 3D culture conditions, hiPSC-derived mesodermal cells (Phase I) were 
seeded in the 3D scaffolds. 
By day 21 the cells in the 3D culture highly expressed the osteoblast markers at 
comparable levels than those from the 2D culture. Importantly, the resulting cell population 
formed calcified structures in vitro and exhibited a sustained expression of BGLAP, a bona fide 
marker of mature osteoblasts. When transplanted in critical-sized calvarial defects in mice, 
hiPSC-derived osteoblasts induced accelerated bone repair as indicated by MicroCT scans and 
histological analysis. In addition, the presence of human nuclear-positive cells in the 
regenerated sites suggested that the hiPSC-derived osteoblasts exerted their positive effect on 
bone repair by engraftment with the host tissue as well as via self-assembled bone-like tissue 
formation (Figure 3).  
      
Figure 3. Representative H&E staining  (left) and immunostaining with human nuclear antigen (right) in calvarias at 4 weeks 
post-transplantation. 
 
4. Conclusion 
A 3D, fully defined, and xeno-free strategy to direct human iPSCs toward osteoblasts was 
established for bone regeneration. The proposed small-molecule mediated protocol produces 
functional hiPSC-derived osteoblast-like cells both in vitro and in vivo. The xeno-free condition, 
the short treatment period, and the stability of the inducers in the developed protocol together 
provide a new step toward the clinical applications of hiPSCs to skeletal regenerative medicine, 
and it may have also significant advantages for drug screening and basic research. 
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